- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01689389
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Argenteuil Cedex, Frankrike
- Research Site
-
Belley, Frankrike
- Research Site
-
Castelmaurou, Frankrike
- Research Site
-
Cavaillon, Frankrike
- Reserach Site
-
Les Mureaux, Frankrike
- Research Site
-
Lille, Frankrike
- Research Site
-
Marseille, Frankrike
- Research Site
-
Montpellier, Frankrike
- Research Site
-
Nimes Cedex, Frankrike
- Research Site
-
Obernai, Frankrike
- Research Site
-
Paris, Frankrike
- Research Site
-
Rennes, Frankrike
- Research Site
-
Saintes Cedex, Frankrike
- Research Site
-
Sens, Frankrike
- Research Site
-
St Dizier, Frankrike
- Research Site
-
St Egreve Cedex, Frankrike
- Research Site
-
Toulouse, Frankrike
- Research Site
-
Tours, Frankrike
- Research Site
-
Ussel Cedex, Frankrike
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- New patients treated with Xeroquel XR
- Patients aged 18 years and over
- Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria
Exclusion Criteria:
- Patient included in a therapeutic trial (Huriet-Serusclat Act)
- Patient refusing to participate in the study
- Pregnant women
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Main study population
All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age. Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months. |
Schizophrenia SoC sample
Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
|
Bipolar SoC sample
Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Descriptive analysis of variables related with how the drug is prescribed and used by the patient.
Tidsramme: At inclusion
|
Variables related with how the drug is prescribed and used by the patient [doses in mg/day, titration (yes/no), time of administration (morning/middle of the day/afternoon/evening), concomitant treatments] are going to be described.
|
At inclusion
|
Description of patient's socio-demographics profile.
Tidsramme: At inclusion
|
Age, gender, educational and professional status, co-habitation are going to be described.
|
At inclusion
|
Descriptive analysis of medical history.
Tidsramme: At inclusion
|
Diagnosis, family history of psychiatric disorders, number of suicidal attempts within the last 12 months, co-morbidities, treatments received during the last 12 months, laboratory and exam data will be included in the description.
|
At inclusion
|
Severity of the disease measured by Clinical Global Impressions Scale - Severity (CGI-S).
Tidsramme: At inclusion
|
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients. |
At inclusion
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in Clinical Global Impressions Scale - Severity (CGI-S) during the treatment.
Tidsramme: From baseline to 12 months
|
The Clinical Global Impressions Scale - Severity (CGI-S) assesses the clinician's impression of the current state of the patient's illness. The following scores can be given: 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill patients. |
From baseline to 12 months
|
Quetiapine XR and concomitant treatment stop, stop date, reasons to stop, restart, restart date, reasons to restart.
Tidsramme: From baseline to 12 months
|
From baseline to 12 months
|
|
Descriptive analysis of the treatment changes: drug switches.
Tidsramme: From baseline to 12 months
|
From baseline to 12 months
|
|
Description of patterns of healthcare management resource use related with psychiatric disorders under investigation.
Tidsramme: From baseline to 12 months
|
From baseline to 12 months
|
|
Change in Body Mass Index (BMI).
Tidsramme: From baseline to 12 months
|
From baseline to 12 months
|
|
Laboratory tests- cholesterol.
Tidsramme: From baseline to 12 months
|
Blood test- cholesterol.
|
From baseline to 12 months
|
Descriptive analysis of all adverse events.
Tidsramme: From baseline to 12 months
|
From baseline to 12 months
|
|
Relapses (only for the schizophrenia subpopulation).
Tidsramme: From baseline to 12 months
|
New psychiatric hospitalisation, deterioration of the CGI-S (Clinical Global Impressions Scale - Severity) by at least 3 points for a baseline score of 1, at least 2 points for a baseline score of 2 or 3, at least 1 point for a baseline score of 4.
|
From baseline to 12 months
|
Laboratory tests- glycemia.
Tidsramme: From baseline to 12 months
|
Blood test- glycemia.
|
From baseline to 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Bruno FALISSARD, Pr, Paris
- Hovedetterforsker: Pierre-Michel LLORCA, Pr, Clermont-Ferrand
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NIS-NFR-SER-2012/1
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .